OUTCOMES OF THE SELF-INJECTION ASSESSMENT QUESTIONNAIRE IN RHEUMATOID ARTHRITIS, AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS PATIENTS RECEIVING GP2015 (ETANERCEPT BIOSIMILAR) IN A REAL-WORLD STUDY: FINAL RESULTS FROM COMPACT STUDY

被引：0
|
作者：
Schmalzing, M. [1 ]
Askari, A. [2 ]
Sheeran, T. [3 ]
Jathanakodi, S. [4 ]
Both, C. [4 ]
Kellner, H. [5 ]
机构：
[1] Wuerzburg, Univ Hosp, Dept Internal Med 2, Rheumatol Clin Immunol, Wurzburg, Germany
[2] Robert Jones & Agnes Hunt Orthoped Hosp NHS Fdn T, Rheumatol, Oswestry, Shrops, England
[3] Univ Wolverhampton, New Cross & Cannock Chase Hosp, Dept Rheumatol, Wolverhampton, England
[4] Sandoz Hexal AG, Rheumatol, Holzkirchen, Germany
[5] Hosp Neuwittelsbach, Ctr Rheumatol & Gastroenterol, Munich, Germany
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
关键词：
Rheumatoid arthritis; Spondyloarthritis; Patient reported outcomes;
D O I：
10.1136/annrheumdis-2023-eular.442
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0419
引用
收藏
页码：1397 / 1397
页数：1
相关论文
共 50 条
  • [31] Real-world effectiveness of golimumab in adult patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis and an inadequate response to initial TNFi therapy in Greece: the GO-BEYOND prospective, observational study
    Panagiotis Athanassiou
    Dimitrios Psaltis
    Athanasios Georgiadis
    Gkikas Katsifis
    Athina Theodoridou
    Souzana Gazi
    Prodromos Sidiropoulos
    Maria G. Tektonidou
    Andreas Bounas
    Anna Kandyli
    Periklis Vounotrypidis
    Grigorios T. Sakellariou
    Dimitrios Vassilopoulos
    Zhiping Huang
    Evangelia Petrikkou
    Dimitrios Boumpas
    Rheumatology International, 2023, 43 : 1871 - 1883
  • [32] Phase 3 Equira 48 Week Study Results Demonstrated No Impact on Efficacy and Safety When Patients with Moderate-to-Severe Rheumatoid Arthritis Were Switched between Reference Etanercept (ETN) and GP2015, an Etanercept Biosimilar
    Kavanaugh, Arthur
    Matucci-Cerinic, Marco
    Schulze-Koops, Hendrik
    Buch, Maya
    Allanore, Yannick
    Kucharz, Eugeniusz J.
    Babic, Goran
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [33] Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study
    Matucci-Cerinic, Marco
    Allanore, Yannick
    Kavanaugh, Arthur
    Buch, Maya H.
    Schulze-Koops, Hendrik
    Kucharz, Eugeniusz J.
    Woehling, Heike
    Babic, Goran
    Poetzl, Johann
    Davis, Adanna
    Schwebig, Arnd
    RMD OPEN, 2018, 4 (02):
  • [34] Etanercept Biosimilar GP 2015 (Erelzi®) in Rheumatic Diseases: Interim Analysis of Real-World Data from COMPACT: A Multicentric, Prospective, Observational Cohort Study
    Schmalzing, Marc
    Askari, Ayman
    Walsh, David
    Castro, Maria Carmen
    De Toro, Francisco J.
    Jeka, Slawomir
    Kellner, Herbert
    Friccius-Quecke, Hilke
    Furlan, Fabricio
    Hachaichi, Sohaib
    Sheeran, Tom
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [35] Real-World Experience with an Adalimumab Biosimilar (ABP 501) in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis in Europe: Results from the Adelphi Disease Specific Programme
    Jin, Ran
    Haughton, James M.
    Goddard, Emily J.
    Courmier, Delphine
    Radziszewski, Waldemar
    Meadows, Rachael H.
    Piercy, James
    Cohen, Stanley
    RHEUMATOLOGY AND THERAPY, 2025,
  • [36] Real-world effectiveness and retention rate of upadacitinib in patients with rheumatoid arthritis: results from a multicentre study
    Baldi, Caterina
    Gentileschi, Stefano
    Li Gobbi, Francesca
    Cazzato, Massimiliano
    Delle Sedie, Andrea
    Gaggiano, Carla
    D'Ignazio, Emilio
    Lepri, Gemma
    De Lorenzo, Chiara
    Nannini, Carlotta
    Niccoli, Laura
    Panaccione, Anna
    Di Cato, Luca
    Di Matteo, Andrea
    Picchianti-Diamanti, Andrea
    Guiducci, Serena
    Frediani, Bruno
    Benucci, Maurizio
    CLINICAL AND EXPERIMENTAL MEDICINE, 2025, 25 (01)
  • [37] Psoriasis Impact on Patient-Reported Outcomes in Psoriatic Arthritis in a Real-World Setting: Results from the APOPSIS Study
    Athanassiou, Panagiotis
    Theodoridou, Athina
    Koukli, Eftychia Maria
    Georgountzos, Athanasios
    Vlachoyiannopoulos, Panagiotis
    Kallitsakis, Ioannis
    Sakkas, Lazaros
    Dapola, Aikaterini Matsouka
    Gazi, Souzana
    Georgiou, Panagiotis
    Gorecki, Patricia
    Gkamaloutsos, Christos
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [38] Psychometric Assessment and Correlation of Psoriatic Arthritis Outcome Measures in Real-World: Results from the COMPLETE-PsA Study
    Khraishi, Majed
    Bessette, Louis
    Haraoui, Boulos
    Setty, Yatish
    Stewart, Jaqueline
    Remple, Valencia
    JOURNAL OF RHEUMATOLOGY, 2019, 46 (07) : 850 - 850
  • [39] Efficacy of switching from originator etanercept to biosimilar YLB113 in real-world patients with rheumatoid arthritis: A retrospective 12 months follow-up study
    Sakane, Hideo
    Yonemoto, Yukio
    Okamura, Koichi
    Suto, Takahito
    Inoue, Makoto
    Mitomi, Hirofumi
    Tsuchida, Kosei
    Kaneko, Tetsuya
    Tamura, Yasuyuki
    Chikuda, Hirotaka
    JOURNAL OF ORTHOPAEDIC SURGERY, 2024, 32 (02)
  • [40] BENEFIT STUDY: A PAN-EUROPEAN OBSERVATIONAL STUDY TO EVALUATE REAL-WORLD EFFECTIVENESS OF SB4 FOLLOWING TRANSITION FROM ORIGINATOR ETANERCEPT (ETN) IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) OR AXIAL SPONDYLOARTHRITIS (AXSPA)
    Krueger, Klaus
    Selmi, Carlo
    Cantagrel, Alain
    Hernandez, Abad
    Freudensprung, Ulrich
    Rezk, Mourad Farouk
    Addison, Janet
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 717 - 718
12345